A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Assess the Tolerability, Safety, and Pharmacokinetics of Single Ascending Oral Tablet Doses of OPC-224333 in Healthy Male and Female Subjects (Arm 1)
Latest Information Update: 25 Mar 2022
At a glance
- Drugs OPC-224333 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 25 Mar 2022 New trial record